1. Home
  2. AMS vs AKTX Comparison

AMS vs AKTX Comparison

Compare AMS & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Shared Hospital Services

AMS

American Shared Hospital Services

HOLD

Current Price

$1.82

Market Cap

13.2M

Sector

Health Care

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.13

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMS
AKTX
Founded
1980
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
11.5M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
AMS
AKTX
Price
$1.82
$0.13
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.53
AVG Volume (30 Days)
3.8K
348.3K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
230.00
N/A
EPS
N/A
N/A
Revenue
$19,714,000.00
N/A
Revenue This Year
$3.81
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.81
N/A
52 Week Low
$1.79
$0.13
52 Week High
$3.11
$1.58

Technical Indicators

Market Signals
Indicator
AMS
AKTX
Relative Strength Index (RSI) 23.83 25.67
Support Level N/A N/A
Resistance Level $2.19 $0.27
Average True Range (ATR) 0.05 0.03
MACD -0.03 -0.01
Stochastic Oscillator 7.35 0.32

Price Performance

Historical Comparison
AMS
AKTX

About AMS American Shared Hospital Services

American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: